Astellas_44th_JPMorgan_Healthcare_Conference_presentation_20260112_unlocked.pdf

1、2026 ASTELLAS PHARMA INC.AND ITS AFFILIATES.Astellas Pharma Inc.J.P.Morgan Healthcare Conference 2026Naoki OkamuraPresident and CEOJanuary 12th,2026Outcomesthat matter to patientsCostto the healthcare system of delivering those outcomesVALUE=On the forefront to healthcare change to turn innovative s

2、cience into VALUE for patients32026 ASTELLAS PHARMA INC.AND ITS AFFILIATES.1445.525.54.110.7328 billion($2.26 billion)R&D expenses-to-revenue ratio of 17%70 countriesOver 172M patients in 103 countries74($0.51)FY20FY21FY22FY23FY247470605042FY2578Established MarketsChinaInternational MarketsWho we ar

3、e:Astellas at a glanceConverted at 1 USD =145 JPYCore OP definition changed from FY2024;excludes other income,other expenses,amortization of intangible assets,gains on disposal of intangible assets,and equity in earnings of affiliates from operating income on a full basis.*Cumulative number of patie

4、nts(estimated)who have been prescribed Astellas products from 1994 to the end of September 2024.1.9 trillion ($13.1 billion)FY20FY21FY22FY23FY241.2trillion1.3trillion1.5trillion1.6trillion1.9trillion$JPY 0.5 trillionJPY 1 trillionJPY 1.5 trillionJPY 2 trillionCorporate Strategic Plan 2021FY252.0tril

5、lionFY20FY21FY22FY23FY24274.7 billion248.9billion323.9billion276.9 billion392.4 billionJPY 100 billionJPY 200 billionJPY 300 billionJPY 400 billionCorporate Strategic Plan 202122%20%18%16%14%12%10%8%392.4 billion/20.5%($2.7 billion)22.019.221.3FY25490.0 billionSALES REVENUEJapanCORE OPERATING PROFIT

6、/MARGIN SALES REVENUE BY REGION(%)R&D EXPENSESOPERATING COUNTRIESSHAREHOLDER RETURN(DIVIDEND)DEVELOPMENT AND SUPPLY OF GROUNDBREAKING NEW MEDICINES*20.517.324.1Numbers in red within each box represent the actual results for FY24(FY3/25).In the chart,red bars represent actuals,and yellow bars represe